Shares of Histogenics Corporation (NASDAQ:HSGX) fell -5.45% to reach at $0.29 during previous trading session. The company has experienced volume of 10,789,562 shares while on average the company has a capacity of trading 11.15M share.
Histogenics (NASDAQ:HSGX) stock went gangbusters on Monday as the company has statedly inked a deal with another business in the industry.
Pennsylvania-based Ocugen is a developer of gene therapies and other biologics designed to treat rare eye diseases, and the company has agreed to a reverse merger with struggling Massachusetts-based business Histogenics.
Ocugen was founded by Pfizer veteran Shankar Musunuri and University of Colorado professor Uday Kompella.
The move will see Histogenics shareholders collectively hold about 10% of the new, combined company, which will include only Ocugen’s lean team.
However, before the former company’s executives depart from the business, they will try to sell NeoCart, which is its regenerative treatment designed to treat knee cartilages.
The program was dropped by Histogenics in December as the Food and Drug Administration asked to see more data before accepting a BLA for review.
Meanwhile, Ocugen’s last financing round was statedly a $7.5 million Series B closed in 2017, which added to its $6 million in Series A cash.
Ocugen makes its bread and butter from drugs that arose from two platforms that were licensed from harvard’s Schepens Eye Research Institute of Massachusetts Eye and Ear.
One of these formulates therapies known as a nanoemulsion, which is statedly more durable and effective than your run-of-the-mill eye drops, while the other is geared to deliver nuclear hormone receptor that goes into the retina.
HSGX stock is up about 56% on Monday, while gaining another 9.3% after the bell.
Histogenics Corporation (NASDAQ:HSGX) holds the market capitalization of $28.49M along with 91.89M outstanding shares. During the last trade, stock’s minimum price has been reached out at $0.28 while the maximum trading price moved at $0.34. Currently the stock price is moving 266.38% off from the highest level of twelve months and -90.39% above from twelve months low. Histogenics Corporation (NASDAQ:HSGX) marked 52-week highest price level of $3.05 on N/A and 52-week lowest price level of $0.080 on N/A.
As of current trade, Histogenics Corporation (NASDAQ:HSGX) has shown weekly upbeat performance of 72.22%. Its six months performance indicated a bearish -29.93% movement while its yearly performance reflected a negative trend of -88.35%. Year-to-date (YTD) performance of the stock illustrate upbeat trend of 250.68%. Shares of Histogenics Corporation (NASDAQ:HSGX) currently have an ABR of 3.00, derived from a total of 2 opinions. The company’s price sits 56.65% above from its 50-day moving average of $0.1917 and -25.28% below from the stock’s 200-day moving average of $0.2055. The company has Relative Strength Index (RSI 14) of 76.60 along with Average True Range (ATR 14) of 0.03. Its weekly and monthly volatility is 17.65%, 9.69% respectively. The company’s beta value is at 3.42.
Histogenics Corporation currently has a PEG ratio of 0 where as its P/E ratio is 2.90. The company’s price to sales ratio for trailing twelve months is 0 and price to book ratio for most recent quarter is 0, whereas price to cash per share for the most recent quarter is 0. Histogenics Corporation (NASDAQ:HSGX)’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 3.50 along with current ratio for most recent quarter of 3.50. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. Histogenics Corporation (NASDAQ:HSGX) has a Return on Assets of 0. The company currently has a Return on Equity of 0 and Return on Investment of 0.